Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Six Months and Full Year Ending March 31, 2025
May 09, 2024 at 03:00 am EDT
Share
Zeria Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first six months and full year ending March 31, 2025. For the first six months, the company expects Net sales of JPY 41,000 million, Operating profit of JPY 5,600 million, Profit attributable to owners of parent of JPY 4,300 million and Basic earnings per share of JPY 97.55.
For the full year, the company expects Net sales of JPY 83,000 million, Operating profit of JPY 10,000 million, Profit attributable to owners of parent of JPY 7,800 million and Basic earnings per share of JPY 176.95.
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
ZERIA PHARMACEUTICAL CO., LTD. 
